Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633459 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL13633502 | 0.82 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL13633541 | 0.77 | CYP2C9 (0.61) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL13638237 | 0.77 | ALKBH2 (0.64) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL13749114 | 0.74 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL16896993 | 0.70 | LMNA (0.46) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL21014027 | 0.68 | ALDH1A1 (0.56) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL13633501 | 0.68 | KDM4E (0.58) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL16264533 | 0.67 | CYP2C9 (0.51) | KDM4EALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL13633521 | 0.66 | CA12 (0.52) | KDM4EALDH1A1SMN1; SMN2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | PFIZER INC | 2009-11-05 | — | — | US | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563788-B2 | Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents | PFIZER INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191394-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191394-A1 | Antibacterial agents | MRPL21, RPN2, FBL | KDM4E 4500/4885ALDH1A1 637/4885SMN1; SMN2 2248/4885 |
| US-20090275577-A1 | IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | DPYD, TYMP, ITPA | KDM4E 4078/4885ALDH1A1 272/4885SMN1; SMN2 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.